Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

It would appear that Iovance made some adjustments to the PII trial: "The response rate in cervical cancer jumped to 44% from 27% in an earlier test. The results included one complete response, nine partial responses and two unconfirmed partial responses.

"This substantially exceeds the prior response rates reported for 15 patients in October 2018 and reflects a shift to patients with fewer prior lines of treatment and exclusion of prior PD-(L)1 (immuno-oncology) therapy," the analysts said in a note."

I didn't see an exclusion of prior PD-(L)1 therapy in the exclusion criteria for Advaxis (I could have missed it) and, for GOG-0265, "More than half the patients had received at least two prior therapies, beyond initial curative-intent treatment."

So, it's not strictly an apples-to-apples comparison.